Literature DB >> 16149910

Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells.

Xiaoming Liu1, Meihui Luo, Liang N Zhang, Ziying Yan, Roman Zak, Wei Ding, S Gary Mansfield, Lloyd G Mitchell, John F Engelhardt.   

Abstract

We previously reported that spliceosome-mediated RNA trans-splicing (SMaRT), using recombinant adenoviral vectors expressing pre-trans-splicing molecules (PTMs), could partially restore cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel activity to polarized human DeltaF508 CF airway epithelia. Although these studies proved that SMaRT could correct CFTR mRNA defects, recombinant adenoviral infection from the basolateral surface was required because of inefficient infection from the apical membrane. Hence, applications of SMaRT technology for CF gene therapy require further testing with alternative, more clinically viable, vector systems. Furthermore, because recombinant adeno-associated virus (rAAV) vectors have packing limitations with respect to the size of the CFTR transgene insert, SMaRT correction of CFTR has the added attraction of a smaller transgene cassette. In the present study, we investigated whether rAAV vectors could effectively rescue CFTR chloride conductance in polarized human CF airway epithelial cells, using a SMaRT approach. AAV vectors were generated to carry a PTM engineered to bind intron 9 of CFTR pre-mRNA and then trans-splice the normal sequence for human CFTR exons 10-24 into the endogenous pre-mRNA. Human CF polarized airway epithelia were infected from the apical membrane with rAAV2 or rAAV5 CFTR-PTM vectors in the presence of proteasome-modulating agents (doxorubicin and N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal) to enhance transduction. Epithelia were then evaluated for cAMP-sensitive short-circuit currents 2 weeks postinfection. Levels of CFTR correction seen with rAAV2 (1.07 +/- 0.24 microA) and rAAV5 (0.90 +/- 0.20 microA) CFTR-PTM vectors were similar, representing conductance equivalent to 14.2 and 13.6% of that observed in non-CF human polarized epithelia, respectively. RT-PCR analysis demonstrated the existence of wild-type CFTR transcript in CFTR-PTM-corrected epithelia, whereas only DeltaF508 mRNA was detected in polarized cells infected with control rAAV LacZ-PTM vectors. These results provide evidence that rAAV vectors are capable of using SMaRT to correct CFTR function after apical infection of human CF airway epithelia. The ability of CFTR-PTM-mediated correction to maintain endogenous CFTR regulation of the transgene product may further improve the efficacy of gene therapy for CF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16149910     DOI: 10.1089/hum.2005.16.1116

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  25 in total

1.  Using 5'-PTMs to repair mutant beta-globin transcripts.

Authors:  Monique N Kierlin-Duncan; Bruce A Sullenger
Journal:  RNA       Date:  2007-06-07       Impact factor: 4.942

2.  Comparative biology of rAAV transduction in ferret, pig and human airway epithelia.

Authors:  X Liu; M Luo; C Guo; Z Yan; Y Wang; J F Engelhardt
Journal:  Gene Ther       Date:  2007-08-30       Impact factor: 5.250

3.  The design and optimization of RNA trans-splicing molecules for skin cancer therapy.

Authors:  Christina Gruber; Ulrich Koller; Eva M Murauer; Stefan Hainzl; Clemens Hüttner; Thomas Kocher; Andrew P South; Helmut Hintner; Johann W Bauer
Journal:  Mol Oncol       Date:  2013-08-19       Impact factor: 6.603

4.  Replacement of huntingtin exon 1 by trans-splicing.

Authors:  Hansjörg Rindt; Pei-Fen Yen; Christina N Thebeau; Troy S Peterson; Gary A Weisman; Christian L Lorson
Journal:  Cell Mol Life Sci       Date:  2012-07-20       Impact factor: 9.261

Review 5.  Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments.

Authors:  William B Guggino; Liudmila Cebotaru
Journal:  Expert Opin Biol Ther       Date:  2017-07-06       Impact factor: 4.388

Review 6.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

7.  Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium.

Authors:  Wuping Li; Liqun Zhang; Jarrod S Johnson; Wu Zhijian; Joshua C Grieger; Xiao Ping-Jie; Lauren M Drouin; Mavis Agbandje-McKenna; Raymond J Pickles; R Jude Samulski
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

8.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

9.  Exon exchange approach to repair Duchenne dystrophin transcripts.

Authors:  Stéphanie Lorain; Cécile Peccate; Maëva Le Hir; Luis Garcia
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

10.  Biological Differences in rAAV Transduction of Airway Epithelia in Humans and in Old World Non-human Primates.

Authors:  Xiaoming Liu; Meihui Luo; Cyndi Trygg; Ziying Yan; Diana C M Lei-Butters; Carolina I Smith; Anne C Fischer; Keith Munson; William B Guggino; Bruce A Bunnell; John F Engelhardt
Journal:  Mol Ther       Date:  2007-07-31       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.